Top 50 Medical VC (Venture Capital) Funds in Oceania in December 2024
A list of 50 VC (Venture Capital) funds that invest in Medical startups based in Oceania. We rank investors based on the number of investments they made in Medical companies from Oceania. We update this investor list every month.Top 50 Medical VC (Venture Capital) Funds in Oceania in December 2024
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
- Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Series A, Pre-Seed
- Australia, United States, Hong Kong
Portfolio highlights
- Bygen — Bygen delivers high-quality activated carbon products while also facilitating large-scale, long-term carbon dioxide sequestration.
- Ohmie Go — EV charging solutions, shared electric vehicles, shared e-bikes & e-scooters delivered to residents as a premium managed service and amenity - An intelligent way to get EV ready with one seamless experience.
- Sova Health — Sova Health is a precision nutrition platform that guides users towards a healthier lifestyle with personalized nutrition advice based on accurate blood biomarker analysis. Understand what is stopping you from achieving your nutritional goal and get your personalized nutrition plan.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Diraq — Diraq uses spins in silicon quantum dots as qubits. Diraq's qubits are compatible with existing CMOS processes and can fit billions of qubits on a single chip. To transform our world, quantum computers need billions of qubits and Diraq has the IP, the team and the plan to get there.
- Celosia Therapeutics — The Celosia Therapeutics approach is the result of advances in gene therapies and a better understanding of the molecular pathways that contribute to neurodegenerative diseases.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro Shatters the Wi-Fi HaLow Range Record... AgainSets New Benchmark in Connectivity with Record 16 km Wi-Fi HaLow Range Watch Now Smarter,
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Funding Round, Series A
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
- Lenexa Medical — Lenexa Medical is driving towards better healthcare solutions for patients in hospital and aged-care by preventing pressure injuries and empowering clinicans.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Series A, Series B
- Australia, United States, Philippines
Portfolio highlights
- Q-CTRL — Infrastructure software to power the quantum future
- Samsara Eco — Samsara Eco is an enviro-tech company creating infinite recycling to end plastic pollution.
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.
Show more
Investment focus
- Health Care, Information Technology, SaaS
- Seed, Series A, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- Modo — Declutter your mind with our app to boost your mental wellbeing and productivity. modo helps you be present in the moment and focus on what matters most.
- Mindset Health — Mindset Health is a digital therapeutics company that helps people manage chronic health issues like irritable bowel syndrome and anxiety with app-based hypnotherapy.
- More Good Days — More Good Days offers evidence-based pain management programes, education, and health services.
Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Series A, Funding Round
- New Zealand, United States, United Kingdom
Portfolio highlights
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- Watchful — Watchful operates as an AI security company.
- Crimson Education — Crimson Education is the world's leading higher educational consultancy helping students around the world gain admission into leading US and UK universities by up to 400%!
Right Click Capital - Australian Venture Capital Firm
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Series A, Funding Round
- Australia, Singapore, United States
Portfolio highlights
- Cydarm — A case management platform that enables cybersecurity operations teams to collaborate, integrate, and respond with ease.
- Tability — Automate the boring parts of OKRs to cut the waste and spend more time doing what really matters.
- Nomad Atomics — At Nomad Atomics, we develop innovative quantum sensors to solve outstanding problems in mining, underground resources and navigation
Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies.
Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.
Show more
Investment focus
- SaaS, Artificial Intelligence, Software
- Seed, Pre-Seed, Series A
- Australia, United States
Portfolio highlights
- Kapiche — Top-rated customer feedback analytics platform. Instant insights. No setup or coding. Kapiche ingests & analyzes feedback in minutes for real customer insights.
- FloodMapp — Enhance operational efficiency, lead time, situational awareness and decision making using FloodMapp rapid flood mapping software.
- Chipper Cash — Join over 5 million people securely sending and receiving money with Chipper Cash. Great app to send and receive money across a number of countries, highly recommended as a money transfer alternative.
Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Series A, Series B
- Australia, United States, New Zealand
Portfolio highlights
- Build Club — Build Club is a home for big dreams and top builders where the world's top AI builders gather. The company is a team of a global network of engineers, researchers, and founders building at the frontier of AI.
- SafetyCulture — SafetyCulture is the operational heartbeat of working teams around the world. Its mobile-first operations platform leverages the power of human observation to identify issues and opportunities for businesses to improve everyday. More than 28,000 organisations use its flagship products, iAuditor and EdApp, to perform checks, train staff, reportissues, automate tasks and communicate fluidly. SafetyCulture powers over 600 million checks per year, approximately 50,000 lessons per day and millions of corrective actions, giving leaders visibility and workers a voice, in driving safety, quality and efficiency improvements.
- Watchful — Watchful operates as an AI security company.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more
Investment focus
- Health Care, Biotechnology, Therapeutics
- Seed, Series A, Series B
- United Kingdom, United States, Australia
Portfolio highlights
- Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.
Show more
Investment focus
- Software, Financial Services, FinTech
- Seed, Series A, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Safewill — Safewill is Australia's leading online Will writing platform. With thousands of users, Safewill makes it easy and affordable to write your own legally binding will
- BuildPass — Unlock the full potential of your site with easy-to-use AI software to streamline operations, reduce admin tasks, and ensure every project is on track and compliant.
- Ajust — Ajust makes it easy to resolve customer complaints with banks, telcos and energy companies. It's fast, fair and free for consumers.
We invest in Western Australian Innovators with bold ideas and global ambitions. We invest at Seed to Series-A in Western Australian companies.
Show more
Investment focus
- Medical, Health Care, Medical Device
- Seed, Series A
- Australia
Portfolio highlights
- Hola Health — 24 hour online doctors & GP consults via telehealth appointments in 15 minutes. Get instant scripts online, medical certificate online anywhere in Australia.
- VitalTrace — VitalTrace is a medical device company helps mothers and children during labour and delivery by innovating new monitoring devices.
Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more
Investment focus
- Software, Apps, Information Technology
- Seed, Series A, Funding Round
- Australia, United States, New Zealand
Portfolio highlights
- Kry10 — Kry10 is a safe operating system for SDMs.It makes the transition to an intelligent, cloud-connected, and adaptively driven future possible for automobiles, electricity grids, satellites, and medical equipment.
- HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
- SimConverse — SimConverse is a simulation platform that uses generative AI to play the role of any patient, colleague or casualty.
Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!
Show more
Investment focus
- Software, Biotechnology, Financial Services
- Series A, Series B, Series C
- Australia, United Kingdom, United States
Portfolio highlights
- Hysata — Hysata is a developer of hydrogen electrolyzer designed to accelerate the world's shift away from fossil fuels to green hydrogen
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- SafetyCulture — SafetyCulture is the operational heartbeat of working teams around the world. Its mobile-first operations platform leverages the power of human observation to identify issues and opportunities for businesses to improve everyday. More than 28,000 organisations use its flagship products, iAuditor and EdApp, to perform checks, train staff, reportissues, automate tasks and communicate fluidly. SafetyCulture powers over 600 million checks per year, approximately 50,000 lessons per day and millions of corrective actions, giving leaders visibility and workers a voice, in driving safety, quality and efficiency improvements.
Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.
Show more
Investment focus
- Software, Financial Services, FinTech
- Funding Round, Series B, Convertible Note
- Australia, United States, United Kingdom
Portfolio highlights
- Nykaa — Nykaa is an e-Commerce platform for different beauty and wellness products for men and women. They also offer comprehensive content including product reviews, beauty how-to videos, articles by experts, and an e-beauty magazine. Their helpline helps to choose products and services best suited for customer's needs. Nykaa's products areauthentic sourced directly from brands and provide a delivery experience.Nykaa was founded in 2012 by Falguni Nayar and is headquartered in Mumbai, Maharashtra, India.
- Send Payments — SendFX provides cross-border payment and remittance services to individuals and SMEs.
- Send Payments — Send is a fast-growing fintech delivering embedded finance solutions to well-known brands.
Investing in great people solving hard problems to create a better future.
Show more
Investment focus
- Medical Device, Medical, Information Technology
- Seed, Series A
- New Zealand, Australia
Portfolio highlights
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- Kitea Health — Kitea Health creates pressure monitoring implantable medical devices.
- Green Gravity — Green Gravity is an electric power generation company that enables renewable energy transition using energy storage technology.
EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.
Show more
Investment focus
- Software, SaaS, Information Technology
- Series A, Seed, Funding Round
- Australia, New Zealand, United States
Portfolio highlights
- CorePlan — CorePlan is drilling management platform for mining, exploration and drilling companies to digitise their drill program operations. Move from pen, paper and spreadsheets to digital plods, drill planning, rig management, safety compliance and more using our cloud based software.
- Nexl — Nexl believes that CRM systems should be easy-to-use, affordable, and fully automated. They made it their mission to enable law firm's around the world to take back control over their business development efforts and enable them to grow at their full potential.
- InvestorHub — We provide comprehensive access to listed capital raises for institutional, family office and high net worth investors.
Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.
Show more
Investment focus
- Biotechnology, Robotics, Nanotechnology
- Seed
- New Zealand, United States
Portfolio highlights
- Ligar — Providing molecular filtration solutions to companies in the food, beverage, health, therapeutics, flavour and aroma industries. Our unique MIP and Polymer technology enables companies to improve their products and operational processes by extracting, reducing or concentrating flavours or compounds.
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- PowerON — Dielectric Elastomers for Soft Robotics
Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.
Show more
Investment focus
- Software, Information Technology, Health Care
- Funding Round, Seed, Angel
- New Zealand, United States, United Kingdom
Portfolio highlights
- Emerge — Emerge is a financial management tool for businesses. It is a digital-only banking option designed to help Kiwi businesses operate more quickly, economically, and efficiently.
- Yabble — Yabble provides a platform that uses machine learning and natural language processing to help brands connect with more than 62 million consumers globally, and collect data in real-time. Using the solution, clients can build their own surveys and manage their own customer research communities.
- Zenno Astronautics — Zenno Astronautics hardware and software products ensure satellite missions are effectively managed, guaranteeing maximum economic returns and responsible use of space.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more
Investment focus
- Software, Enterprise Software, Information Technology
- Series A, Series B, Funding Round
- United States, Australia, Philippines
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,251,604 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani helps maternity providers quickly identify and manage maternal and fetal risk as well as empowering moms to have healthier pregnancies.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
- Medal — Gamers live here. Medal is the best way to record, clip, edit, and share your gaming clips and videos. Clip, Edit, Share, and Relive your gaming moments.
- ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.
Show more
Investment focus
- Software, E-Commerce, Health Care
- Seed, Series A, Funding Round
- Australia, United States
Portfolio highlights
- OpusXenta — Byond is comprehensive business management software for cemeteries & crematoria, streamlining operations with mapping, record-keeping, sales management and more.
- PaidRight — Know your payroll compliance. Monitor variances in your payroll, get insights and visibility into your own payroll systems and processes so your employees are paid right.
- FLK It Over — Sign documents online easily with FLK it over. Get started with our electronic signature software in just 2 minutes with our 14-day free trial. Try it now!
Resource Capital Funds is a mining-focused alternative investments firm that partners with companies to build strong, successful, and sustainable businesses.
Show more
Investment focus
- Construction, Software, SaaS
- Funding Round, Seed, Convertible Note
- Australia, United States
Portfolio highlights
- SciAps — SciAps specializes in portable analytical instruments with the power to measure any element. Our industry-leading X-ray fluorescence (XRF) and laser-based (LIBS) analyzers are at work across every major industry.
- APE Mobile — APE Mobile develops a paperless site application for contractors in Australia. Its site application comprises features, such as operational forms, safety forms, project management, actions and defects, drawings and documents, and redline markup. David Hayward and Matthew Edwards founded APE Mobile in January 2, 2009. Its headquarters is inLeederville in Australia.
- QuickSafety — Now you can quickly and easily complete Certificate of Compliance in Sydney, Melbourne, Brisbane & New Zealand using the Quicksafety mobile app.
Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.
Show more
Investment focus
- EdTech, Medical, Education
- Seed
- Australia
Portfolio highlights
- PlanCare — Plan Care is a technology platform that helps participants via dedicated plan managers by providing guidance and responding to queries.
- My Mirror — My Mirror is a mental health care center that offers psychology sessions, mental health assessments, and treatment services.
- Andromeda Robotics — At Andromeda, our personalised robot companions are helping Australian aged care teams bring joy and connection to residents to improve wellbeing.
GD1 is a Venture Capital firm that invests with high conviction in exciting technology companies originating from New Zealand. Our team is passionate about creating and growing global businesses, and our goal is to transform NZ made into the next generation of globally disruptive tech solutions.
Show more
Investment focus
- Software, SaaS, Artificial Intelligence
- Seed, Series A, Series B
- New Zealand, United States, China
Portfolio highlights
- Rilla — Demonstrating 90% reduction in cost-to-serve for live-streaming, Rilla is rewiring the content economy, directing the value generated back to creators and their communities.By leveraging audience bandwidth and rewarding them with ownership in the network, the savings are equivalent to a free month subscription every year for a moderate level ofviewership.Founded by the technical founders behind Altered State Machine, acquired for 214m. Together for 5+ ventures, collectively raising 130m+ and valued at 1b+.
- NextWork — Building the best online learning experience to switch careers and upskill. Join the waitlist today, we are waiting for you!
- Type One Energy — At Type One Energy, we are mission-driven to provide sustainable, affordable fusion power to the world over the coming decade.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Pollenizer is a co-founder of start-up web businesses in Australia. They partner with strong founders and take equity stakes at a concept stage on consumer and SaaS businesses. The skill sets cover technology, marketing and capital raising. They also occasionally make seed investments. Their businesses include;* * ** * * * * * * * * * Their team includes;* Phil Morle, ex-CTO of Kazaa, Omnidrive.* Mick Liubinskas, ex-CMO of Kazaa, Tangler, ZaprThey are also investors and partners with
Show more
Investment focus
- E-Commerce, B2B, Marketplace
- Seed, Angel, Funding Round
- Australia
Portfolio highlights
- LawPath — Create legal documents, manage compliance and connect with lawyers on demand. Less stress, more time and better business. Sign up for free.
- CohortIQ — cohortiQ Home Page
- HiveXchange — Designed and built in Australia for the fresh produce industry. Find opportunities, create private offers, make product requests, get notified of deals in real time. Trade easy.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A
- Australia
Portfolio highlights
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under managementand focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series C, Series B, Series A
- United States, Israel, Australia
Portfolio highlights
- IpiNovyx Bio — Orange Grove Bio partners with leading research universities to advance preclinical biotech programs in the oncology space. The company leverages its venture capital and drug development expertise to help patients and build biotech ecosystems.
- Evox Therapeutics — Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectualproperty portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
- Kymera Therapeutics — Advancing targeted protein degradation to deliver next-generation medicines
K1W1 provides startups and businesses in New Zealand with early and later-stage venture investments.
Show more
Investment focus
- Software, Biotechnology, SaaS
- Seed, Series A, Funding Round
- New Zealand, United States
Portfolio highlights
- Akahu — Akahu provides open banking and open finance infrastructure. We make it simple for people to connect their financial accounts to trusted third parties.
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
- Mint Innovation — Founded in 2016, members of the Mint Innovation team have a strong background in chemistry, biotechnology, and leveraging IP in the industrial sector. They are scaling their technology in their Auckland plant and labs to demonstrate the commercial application of their biometallurgy processes for metal recovery.
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Their goal is to provide money and mentoring to the lifescience community to achieve superior returns for their group, and more clinical innovation for the community.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series B, Seed
- United States, Israel, Australia
Portfolio highlights
- Coviu — Video chat, secure messaging, appointment booking, prescription delivery, in-app assessments, in-call tools. Made for practitioners, clinics and hospitals.
- Capillary Biomedical — Make diabetes management easier with insulin pumps and other innovative products and services from Tandem Diabetes Care.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Angeloop provides a social and business intelligence platform for Startups and Investors to leverage those networks to their full extent.
Show more
Investment focus
Portfolio highlights
- Gelomics — Gelomics operates as a biotechnology company. Gelomics provides 3D cell culture technologies.
HTC Corp is engaged in the design, development, and manufacture of smartphones and tablets in Taiwan.The company offers PDA phones and smartphones for mobile operators and distributors in Europe, the United States, and Asia. These machines are available as HTC devices and as products individually customized for operators and device partners.The company provides its own HTC self-branded products as well as supports operator-branded products and original equipment manufacturer (OEM) partners. It owns Dopod as a subsidiary company and is a member of the Open Handset Alliance.The company’s products are sold under various brand names such as HTC, Dopod, and Qtek and are often rebranded by major telecommunication carriers. Its products also include pocket PC phones (PDA Phone), ultra mobile phones, HTC kovsky (Sony Ericsson XPERIA X1), and HTC dream (T-mobile G1).HTC Corp was founded by Cher Wang and Peter Chou in 1997. It is headquartered in New Taipei City, Taiwan.
Show more
Investment focus
- Virtual Reality, Software, Augmented Reality
- Series A, Seed, Funding Round
- United States, Taiwan, China
Portfolio highlights
- Hexa — Elevate your eCommerce experience with a 3D tech-stack that lets you create, manage, analyze, and distribute your 3D commerce assets.
- Camsense — Camsense focuses on R&D and manufacturing of vision space positioning technology. It provides customers with highly precise sensors with its self-developed core algorithm and chips. Its products can be applied in consumer robots, industrial test, and surgeries.
- Inworld AI — AI for Metaverse
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
- OncoPrecision — We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives.
- Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
Auckland University's commercialisation arm
Show more
Investment focus
- Medical Device, SaaS, Audio
- Seed, Pre-Seed
- New Zealand
Portfolio highlights
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- Formus Labs — Formus Labs develops software technologies for orthopedic planning and analysis. Our mission is to improve outcomes and efficiencies through seamless and highly scalable integration of AI and computational modelling in the orthopedic clinical workflow. Based in Auckland, New Zealand, Formus Labs draws on over 10 years of research andcommercialisation experience, with operations in New Zealand, Australia, and soon in the USA.
At UniServices, we partner with the University of Auckland to transform ideas into real-world solutions that impact globally.
Show more
Investment focus
- Medical, Marketing, Health Care
- Seed, Pre-Seed
- New Zealand
Portfolio highlights
- eVouch — eVouch is the most powerful marketing tool we've used to build an organic community. We've experienced elevated brand trust while reaching an audience we never thought possible. Using customers to market to their friends is simply genius.
- Kitea Health — Kitea Health creates pressure monitoring implantable medical devices.
We exist to serve great entrepreneurs with honest advice and education, investment capital that is fair, and an open door to our international network and connections.
Show more
Investment focus
- Animation, Information Technology, Software
- Seed, Pre-Seed, Funding Round
- New Zealand
Portfolio highlights
- Segna — Extract trends across your users. Build products that they love.
- Space Rock Games — Space Rock Games is the developer behind Criminals Within - a cooperative-only action game set in a medieval fantasy kingdom. Sign up to receive exclusive development updates!
- Floating Rock Studio — Floating Rock Studio
Privately Held Companies
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Series C
- United States, Canada, New Zealand
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
- Reprieve Cardiovascular — Reprieve Cardiovascular is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients.
Jelix is an early-stage venture capital firm backing daring founders in Australia and New Zealand.
Show more
Investment focus
- Software, SaaS, Artificial Intelligence
- Seed, Series A, Funding Round
- Australia, New Zealand
Portfolio highlights
- Gelomics — Gelomics operates as a biotechnology company. Gelomics provides 3D cell culture technologies.
- Fugu — Cheap green carbon at scale for the dawn of the e-fuel age
- Fugu Carbon — Fugu Carbon is a machinery manufacturing company that helps in carbon dioxide removal (CDR) technology from air.
Get Award Winning cover. Voted Outstanding Value Health Insurance for 16 Consecutive Years. Choose from flexible cover options & join online today.
Show more
Investment focus
- Medical, Health Care, Information and Communications Technology (ICT)
- Corporate Round
- Australia
Portfolio highlights
- Medinet — Streamline your medical practice and improve employee wellness with Medinet's comprehensive practice management and corporate health services.
Tyson & Blake We identify growth companies with unique approaches and innovative technologies that have the potential to make a profound contribution to society.We develop inspiring businesses that share our goals and our values.We create a positive impact and long-term value for our investors, the companies we invest in and the communitieswe live in.
Show more
Investment focus
- Medical, Facial Recognition, Artificial Intelligence
- Seed, Funding Round
- Australia
Portfolio highlights
- Strong Room — Software that enables high-strength care through streamlined workflows, continuous analytics, surfaced insights and safeguarded data.
Watermark Funds Management. A specialist long/short investor offering attractive returns while hedging share market risks.
Show more
Investment focus
- Medical, Software, Health Care
- Series A
- Australia
Portfolio highlights
- Artrya — We use artificial intelligence for accurate cardiac imaging and heart disease diagnoses. Learn more about Salix, our noninvasive diagnostic support solution.
The New Zealand Growth Capital Partners (formerly New Zealand Venture Investment Fund) was established to support early-stage technology companies and to stimulate private investment into this space.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Series A, Funding Round
- New Zealand, United States
Portfolio highlights
- Aquafortus — Aquafortus specializes in providing enviornmental services and commercializes proprietary zero liquid discharge technology.
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- Marama Labs — Marama Labs provides an integrated chemical analysis platform that empowers customers to optimize their production processes and match their products and brands to customer needs, with ease.
With origins in owning and operating Australian pharmacies, Soul Patts has evolved into a diversified investment house investing across a range of industries and asset classes, including listed equities, private equity, credit, and property.
Show more
Investment focus
- Software, Hotel, Men's
- Funding Round, Series A
- Australia
Portfolio highlights
- Artrya — We use artificial intelligence for accurate cardiac imaging and heart disease diagnoses. Learn more about Salix, our noninvasive diagnostic support solution.
- InStitchu — InStitchu is an online custom clothier specializing in tailor made menswear. Customers are able to design custom made garments online which are then made to their exact measurements.InStitchu provides tailor made, high quality menswear through a simple online ordering process. Once a customer has added measurements to their profile, a suit orshirt can be ordered in a few minutes and on its way in two weeks. There are multiple ways for a customer to get their measurements perfected and enjoy that “perfect fit” InStitchu customers keep coming back for - our measurement guide will take you on a journey from your living room to the hustle and bustle of our tailor’s studio. Customers can choose from a wide range of globally sourced high quality wool and cotton fabrics, and when you’ve chosen, we’ll deliver your design right to your door. This new approach to shopping is stress free and cuts out the middleman, allowing us to deliver customers luxury tailor made suits and shirts without the high price tag.
- SiteMinder — SiteMinder is the world’s leading open hotel commerce platform, ranked among technology pioneers for opening up every hotel’s access to online commerce. It’s this central role that has earned SiteMinder the trust of tens of thousands of hotels, across 150 countries, to sell, market, manage and grow their business. The global company, headquarteredin Sydney with offices in Bangkok, Berlin, Dallas, Galway, London and Manila, generated more than 100 million reservations worth over US$35 billion in revenue for hotels in the last year prior to the start of the pandemic.
SG Hiscock
Show more
Investment focus
- Software, Legal, Medical
- Series A, Funding Round
- Australia
Portfolio highlights
- Artrya — We use artificial intelligence for accurate cardiac imaging and heart disease diagnoses. Learn more about Salix, our noninvasive diagnostic support solution.
- Immediation — Sophisticated video conferencing for dispute resolution and legal practice. Built by Lawyers, for Lawyers. Start your free 14-day trial today.
- Marketplacer — We make it easy for you to integrate third-party seller inventory into your platforms, opening up a world of growth opportunities.
Skip Capital is a private investment fund investing in technology and infrastructure
Show more
Investment focus
- Software, Artificial Intelligence, SaaS
- Series A, Seed, Series B
- Australia, United States, Canada
Portfolio highlights
- Atticus — Atticus makes fact-checking quick, collaborative and secure, so you can spend less time on process and more on the things that matter.
- BurnBot — Burnbot is a tech forward provider of wildfire mitigation, vegetation management, and prescribed fire operations. We offer force-multiplying solutions that reduce the risk of wildfire damage for critical infrastructure, firefighting agencies, agriculture, private enterprise, public lands, conservati
- Archistar.ai — Archistar's world-first artificial intelligence helps property professionals find profitable land development sites, assess for feasibility and generate dozens of architectural design strategies - all within a few minutes
CVC has seven complementary strategies across private equity, secondaries and credit, through which we invest on behalf of pension funds and other leading institutions
Show more
Investment focus
- Software, Financial Services, Retail
- Private Equity, Post-IPO Equity, Funding Round
- United States, United Kingdom, Indonesia
Portfolio highlights
- Odevo — We are on a mission to become the leading force within property management and residential services through the combined power of people and technology. Join us.
- Hempel — We help you protect your most valuable assets with our high-quality coatings
- Sunday Natural — Sunday Natural develops various kinds of organic, plant-based, and healthy products. It offers vitamins, supplements, fruits, vegetables, tea, skincare items and cosmetics that are made with scientific and clinical research. Sunday Natural is based in Berlin, Germany.
Investors by industry
Biotech
Proptech
Gaming
FinTech
Health Care
Community
Google
Marketplace
Climate
Consumer
Artificial intelligence
Impact
Energy
Hardware
EdTech
Sustainability
Venture Capital
Clean Energy
B2B
Real Estate
Publishing
Payments
Big Data
Retail
Organic Food
Web3
Education
Finance
Food and Beverage
Video Games
Infrastructure
Financial Services
Photography
Beauty
Medical
Wellness
Social Media
Social Network
Android
Construction
Art
Local
Legal
Digital Media
Manufacturing
eSports
Sports
Music
Mobile
Internet
Enterprise Software
Franchise
Email
Travel
Mobile Advertising
Biotechnology
Recruiting
Hospitality
Fitness
Platforms
Cannabis
Medical Device
Social
Automotive
Crowdfunding
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Social Impact
Restaurants
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Canada
New Zealand
Ireland
United States
Qatar
Saudi Arabia
Spain
Sri Lanka
China
Middle East
Africa
Indonesia
Europe
Armenia
Singapore
Oceania
Brazil
Japan
South Africa
Vietnam
LATAM
Asia
Denmark
Costa Rica
Bermuda
Egypt
Croatia
Gibraltar
Algeria
Estonia
Ecuador
Greece
Chile
Bulgaria
Ethiopia
Hong Kong
Faroe Islands
France
Ghana
Czech Republic
Hungary
Georgia
Belgium
Finland
Bahrain
Belarus
Belize
Barbados
Lebanon
Mali
Liberia
Malta
Liechtenstein
Malaysia
Italy
Panama
Myanmar
Mauritius
Nicaragua
Philippines
Puerto Rico
Tunisia
Uganda
Sierra Leone
Senegal
San Marino
Uzbekistan
Seychelles
Togo
El Salvador
Rwanda
Russian Federation
Tanzania
Ukraine
Zimbabwe
Uruguay
Serbia
Taiwan
Venezuela
Tajikistan
Lithuania
Sweden
Turkey
Poland
Thailand
Zambia
Portugal
Slovenia
Dominican Republic
Israel
Jersey
Azerbaijan
Norway
Iraq
Iceland
Bahamas
Namibia
Nigeria
United Arab Emirates
Jamaica
Morocco
Honduras
Mexico
Bolivia
Isle of Man
Luxembourg
Peru
Albania
Kuwait
Pakistan
Bangladesh
Argentina
Grenada
Jordan
Romania
Kazakhstan
Kenya
Cayman Islands
Cambodia
Cyprus
Latvia
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Marshall Islands
VC (Venture Capital) Funds in Oceania by industry
Restaurants
Crowdfunding
Venture Capital
Retail
Real Estate
Financial Services
Cryptocurrency
Finance
Payments
Food and Beverage
Video Games
Medical
Wine And Spirits
Wellness
Medical Device
Biotech
Internet
Email
Social Network
Art
Manufacturing
Music
Digital Media
Android
Mobile
Legal
Construction
Software
eSports
Enterprise Software
Fitness
Hospitality
Automotive
CleanTech
Travel
Platforms
FinTech
Biotechnology
Cannabis
Enterprise
Consumer
Health Care
Energy
EdTech
Climate
Sustainability
Proptech
Marketplace
SaaS
Community
Hardware
Social
Beauty
Fashion
Web3
B2B
Life Science
Big Data
Education
Clean Energy
Infrastructure
Oil and Gas
Renewable Energy
Social Media
Non Profit
Social Impact
Mobile Apps
Publishing
InsurTech
Blockchain
Sports
Recruiting
Transportation
Impact
Agriculture (agtech)
Gaming
Media (entertainment)
Artificial intelligence